Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

被引：0
|
作者：
Joseph Gathe
Jose R. Arribas
Jan Van Lunzen
Will Garner
Rebecca M. Speck
Randall Bender
Sanatan Shreay
Thai Nguyen
机构：
[1] Therapeutic Concepts,
[2] PA,undefined
[3] Hospital La Paz,undefined
[4] IdiPaz,undefined
[5] Universitaetsklinikum Hamburg-Eppendorf,undefined
[6] Gilead Sciences,undefined
[7] Inc.,undefined
[8] Evidera,undefined
来源：
The Patient - Patient-Centered Outcomes Research | 2015年 / 8卷
关键词：
Physical Component Summary; Mental Component Summary; Tenofovir Disoproxil Fumarate; Mental Component Summary Score; Emtricitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：445 / 454
页数：9
相关论文
共 33 条
  • [1] Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF
    Gathe, Joseph
    Arribas, Jose R.
    Van Lunzen, Jan
    Garner, Will
    Speck, Rebecca M.
    Bender, Randall
    Shreay, Sanatan
    Thai Nguyen
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (05): : 445 - 454
  • [2] Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF
    Anthony Mills
    Will Garner
    Anton Pozniak
    Juan Berenguer
    Rebecca M. Speck
    Randall Bender
    Thai Nguyen
    [J]. The Patient - Patient-Centered Outcomes Research, 2015, 8 : 359 - 371
  • [3] Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF
    Mills, Anthony
    Garner, Will
    Pozniak, Anton
    Berenguer, Juan
    Speck, Rebecca M.
    Bender, Randall
    Thai Nguyen
    [J]. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2015, 8 (04): : 359 - 371
  • [4] Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
    Arribas, Jose R.
    Pialoux, Gilles
    Gathe, Joseph
    Di Perri, Giovanni
    Reynes, Jacques
    Tebas, Pablo
    Thai Nguyen
    Ebrahimi, Ramin
    White, Kirsten
    Piontkowsky, David
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (07): : 581 - 589
  • [5] Simplification to elvitegravir/cobicistat/emtricitabine/tenofovir DF from ritonavir-boosted protease inhibitor plus emtricitabine/tenofovir DF maintains HIV suppression and improves fasting triglycerides at week 48
    Mounzer, K.
    Rashbaum, B.
    Lucasti, C.
    Melbourne, K.
    Kwon, P.
    Nguyen, T.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A26 - A27
  • [6] Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
    Pozniak, Anton
    Markowitz, Martin
    Mills, Anthony
    Stellbrink, Hans-Juergen
    Antela, Antonio
    Domingo, Pere
    Girard, Pierre-Marie
    Henry, Keith
    Thai Nguyen
    Piontkowsky, David
    Garner, Will
    White, Kirsten
    Guyer, Bill
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (07): : 590 - 599
  • [7] Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects at 48 weeks
    DeJesus, E.
    Orkin, C.
    Rockstroh, J.
    Molina, J-M
    White, K.
    Wei, X.
    Plummer, A.
    Kearney, B.
    Cheng, A.
    [J]. HIV MEDICINE, 2012, 13 : 9 - 9
  • [8] Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
    Orkin, Chloe
    Molina, Jean-Michel
    Negredo, Eugenia
    Arribas, Jose R.
    Gathe, Joseph
    Eron, Joseph J.
    Van Landuyt, Erika
    Lathouwers, Erkki
    Hufkens, Veerle
    Petrovic, Romana
    Vanveggel, Simon
    Opsomer, Magda
    [J]. LANCET HIV, 2018, 5 (01): : E23 - E34
  • [9] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
    DeJesus, Edwin
    Rockstroh, Juergen K.
    Henry, Keith
    Molina, Jean-Michel
    Gathe, Joseph
    Ramanathan, Srinivasan
    Wei, Xuelian
    Yale, Kitty
    Szwarcberg, Javier
    White, Kirsten
    Cheng, Andrew K.
    Kearney, Brian P.
    [J]. LANCET, 2012, 379 (9835): : 2429 - 2438
  • [10] Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Martorell, Claudia T.
    de Wet, Joseph
    Stellbrink, Hans-Jurgen
    Molina, Jean-Michel
    Post, Frank A.
    Valero, Ignacio Perez
    Porter, Danielle
    Liu, Yapei
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    [J]. LANCET HIV, 2017, 4 (05): : E205 - E213
1234